ClinicalTrials.gg
Active, not recruitingNCT07183306Updated Oct 29, 2026

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

A Phase 1/2 interventional study of HT-101 and HT-102 in Chronic Hepatitis B, sponsored by Suzhou HepaThera Biotech Co., Ltd.. Active, not recruiting at 7 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Suzhou HepaThera Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2024, registered Sep 2025).
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
181st of 273
86 · median 120
Started
2024
with 33 others
Phase 1/2
12 of 375
1 open now
Primary completion
2027-08
later than 72 of 109 live
Registered
333rd of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 181st largest by enrollment of the 273 interventional ones that give a count, is one of 34 that started in 2024, is one of 12 in phase 1/2, reaches primary completion later than 72 of the 109 other live ones, and was the 333rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study is A multicenter, open-label, partial multiple-ascending doses phase1b/2 in which participants with chronic hepatitis B virus (HBV) infection will receive HT-101 and/or HT-102 and be assessed for safety, tolerability, Pharmacokinetics, and Pharmacodynamics. Approximately 86 patients with chronic hepatitis B infection were planned to be recruited. Among them, Group A and Group AA received HT-101 injection, administered once every 4 weeks (Q4W), at least for 24 weeks. Group B received HT-102 injection, administered Q4W for 24 weeks and sequential dosed with HT-101 for another 24 weeks. Groups C, D, and E received HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks. During the study period, all subjects received nucleoside (acid) analogues (NAs) treatment.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were eligible for inclusion into the study if they met each of the following criteria:

Patient with CHB

Male subjects weighed ≥ 50.0 kg, female subjects weighed ≥ 45.0 kg, with a (BMI) between 19.0 and 28.0 kg/m\^2 (inclusive); Chronic infection for >/= 6 months; The quantitation level of HBsAg was > 100 IU/mL and \<3000 IU/mL; The quantitation level of HBV DNA \<LLOQ;

  • On Nas therapy for >/= 6 months at the time of screening

Subjects promised to use effective for at least 1 month before screening, and have no fertility, donate sperm or eggs and voluntarily take highly effective physical contraception (including partners) during the trial and within 3 months after the end of the trial;

Exclusion criteria

Exclusion Criteria:

  • Subjects were excluded from the study if one or more of the following criteria were applicable

Participants with history of drug allergy or specific allergy; Participants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems; Participants with history of active pathological bleeding, or bleeding tendency; Participants with abnormal results of physical examination, vital sign examination, examination, laboratory test in the screening period which were judged as by clinicians; Participants with significant liver fibrosis or cirrhosis; Participants with symptoms or a history of hepatic decompensation; Participants with a history or suspected risk of liver cancer;

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Experimental: Cohort A (HT-101)

    Participants will receive received HT-101 injection, administered once every 4 weeks (Q4W), at least for 24 weeks

    Drug: HT-101

  • Experimental
    Experimental: Cohort AA (HT-101)

    Participants will receive received HT-101 injection, administered once every 4 weeks (Q4W), at least for 24 weeks

    Drug: HT-101

  • Experimental
    Experimental: Cohort B (HT-102;HT-101)

    Participants will receive HT-102 injection, administered Q4W for 24 weeks and sequential dosed with HT-101 for another 24 weeks

    Drug: HT-101 · Drug: HT-102

  • Experimental
    Experimental: Cohort C (HT-101 + HT-102)

    Participants will receive HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks

    Drug: HT-101 · Drug: HT-102

  • Experimental
    Experimental: Cohort D (HT-101 + HT-102)

    Participants will receive HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks

    Drug: HT-101 · Drug: HT-102

  • Experimental
    Experimental: Cohort E (HT-101 + HT-102)

    Participants will receive HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks

    Drug: HT-101 · Drug: HT-102

Interventions

  • DrugHT-101

    HT-101 given by subcutaneous injection.

  • DrugHT-102

    HT-102 given by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.

    Time frame: From enrollment to the end of treatment at up to 60 weeks

  2. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From enrollment to the end of treatment at up to 60 weeks

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Cmax of HT-101 and its metabolite in plasma. First administration: Predose 1 hour; Postdose 0.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours. Changes in the concentration of and HT-102 in serum, From Day1 until 36 weeks

    Time frame: HT-101: From predose 1 hour to postdose 24 hours HT-102:UP to 36 weeks

  2. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HT-101 and its metabolite in plasma. First administration: Predose 1 hour; Postdose 0.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours. Changes in the concentration of and HT-102 in serum, From Day1 until 36 weeks

    Time frame: HT-101:From predose 1 hour to postdose 24 hours. HT-102:UP to 36 weeks

  3. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HT-101 and its metabolite from time 0 to last measurable time. First administration: Predose 1 hour; Postdose 0.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours. Changes in the concentration of and HT-102 in serum, From Day1 until 36 weeks

    Time frame: HT-101:From predose 1 hour to postdose 24 hours. HT-102:UP to 36 weeks

  4. Apparent Terminal Elimination Half-life (T1/2)

    T1/2 of HT-101 in plasma. First administration: Predose 1 hour; Postdose 0.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours. Changes in the concentration of and HT-102 in serum, From Day1 until 36 weeks

    Time frame: HT-101:From predose 1 hour to postdose 24 hours. HT-102:UP to 36 weeks

  5. Apparent Plasma Clearance (CL/F)

    CL/F of HT-101 in plasma. First administration: Predose 1 hour; Postdose 0.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours. Changes in the concentration of and HT-102 in serum, From Day1 until 36 weeks

    Time frame: HT-101:From predose 1 hour to postdose 24 hours. HT-102:UP to 36 weeks

  6. Apparent volume of distribution(Vd/F)

    Vd/F of HT-101. First administration: Predose 1 hour; Postdose 0.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours. Changes in the concentration of and HT-102 in serum, From Day1 until 36 weeks

    Time frame: HT-101:From predose 1 hour to postdose 24 hours. HT-102:UP to 36 weeks

  7. Maximum Change of Serum HBsAg From Baseline

    Maximum change of serum HBsAg from Day 1 until 48 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)

    Time frame: Up to 48 weeks

  8. Maximum Change of Serum HBV DNA From Baseline

    Maximum change of serum HBV DNA from Day 1 until 48 weeks (negative values mean reductions from baseline, positive values mean increased from baseline).

    Time frame: Up to 48 weeks

  9. Titers of Anti-drug Antibody (ADA) to HT-102

    ADA analysis for predose 36weeks

    Time frame: UP to 36 weeks

07

Study locations

7 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 31 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Aug 2026 → Aug 2027 and completion May 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 19, 2025
StartActual
Dec 30, 2024
Primary completionEst.
Aug 24, 2027was Aug 2026
CompletionEst.
May 3, 2028was May 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 24, 2026→Aug 24, 2027
Oct 29, 2026
Study completion
May 3, 2027→May 3, 2028
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Aug 24, 2026→Aug 24, 2027
    Study completion May 3, 2027→May 3, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07183306
Lead sponsor
Suzhou HepaThera Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Sep 19, 2025
Start date
Dec 30, 2024
Primary completion
Aug 24, 2027 (estimated)
Completion
May 3, 2028 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HT-101

Start the discussion